Tempus AI, Inc. (NASDAQ:TEM) Stock Has Consensus Target Price of $79.37

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received an average recommendation of “Hold” from the twenty-two analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $79.37.

Several research analysts have recently issued reports on TEM shares. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Needham & Company LLC raised their price target on shares of Tempus AI from $75.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Raymond James Financial set a $80.00 price objective on shares of Tempus AI in a report on Wednesday, September 2nd. Guggenheim increased their target price on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Roth Capital began coverage on Tempus AI in a research note on Tuesday, September 8th. They set a “neutral” rating and a $67.00 target price on the stock.

Tempus AI Price Performance

TEM opened at $76.05 on Friday. The firm has a market cap of $13.87 billion, a PE ratio of -71.75 and a beta of 3.61. The stock has a 50-day moving average price of $71.32 and a 200-day moving average price of $57.25. Tempus AI has a 1 year low of $40.77 and a 1 year high of $89.09. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 2.48.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.16. The company had revenue of $411.54 million for the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. Tempus AI’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.46) EPS. Sell-side analysts predict that Tempus AI will post -1.20 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In related news, CEO Ryan Fukushima sold 700 shares of Tempus AI stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total value of $49,000.00. Following the completion of the sale, the chief executive officer owned 15,874 shares of the company’s stock, valued at $1,111,180. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $70.36, for a total value of $17,590,000.00. Following the completion of the transaction, the chief executive officer directly owned 50,000 shares in the company, valued at approximately $3,518,000. This represents a 83.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,237,227 shares of company stock worth $85,388,983. 24.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors have recently bought and sold shares of the stock. Guardian Partners Inc. increased its holdings in Tempus AI by 8.3% in the 3rd quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock worth $213,000 after acquiring an additional 200 shares in the last quarter. Kestra Private Wealth Services LLC lifted its holdings in Tempus AI by 1.4% during the third quarter. Kestra Private Wealth Services LLC now owns 18,685 shares of the company’s stock valued at $1,530,000 after purchasing an additional 257 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in Tempus AI during the third quarter valued at approximately $27,000. ProShare Advisors LLC boosted its position in shares of Tempus AI by 5.9% in the third quarter. ProShare Advisors LLC now owns 6,500 shares of the company’s stock worth $532,000 after purchasing an additional 360 shares during the period. Finally, Cyndeo Wealth Partners LLC increased its stake in shares of Tempus AI by 6.7% in the third quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock worth $525,000 after purchasing an additional 400 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research.

The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Founded in 2015 by entrepreneur Eric Lefkofsky, Tempus is headquartered in Chicago.